Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 6/20 | 0.58 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1334981 | 1.00 | HCRTR1 (0.58) | HCRTR1HCRTR2MEN1KMT2AGSK3B | |
| SCHEMBL25329990 | 0.88 | HCRTR1 (0.53) | HCRTR1HCRTR2MEN1KMT2AL3MBTL1 | |
| SCHEMBL1332867 | 0.82 | MEN1 (0.50) | HCRTR1HCRTR2MEN1KMT2AGSK3B | |
| SCHEMBL15133185 | 0.82 | MEN1 (0.53) | HCRTR1HCRTR2MEN1KMT2AL3MBTL1 | |
| SCHEMBL16796874 | 0.81 | HCRTR2 (0.64) | HCRTR1HCRTR2MEN1KMT2ASIGMAR1 | |
| SCHEMBL697331 | 0.81 | HCRTR1 (0.52) | HCRTR1HCRTR2MEN1KMT2AGSK3B | |
| SCHEMBL1459146 | 0.81 | HCRTR1 (0.52) | HCRTR1HCRTR2MEN1KMT2AGSK3B | |
| SCHEMBL3508819 | 0.81 | HCRTR1 (0.52) | HCRTR1HCRTR2MEN1KMT2AGSK3B | |
| SCHEMBL1177390 | 0.80 | HCRTR1 (0.49) | HCRTR1HCRTR2MEN1KMT2AGSK3B | |
| SCHEMBL19521008 | 0.80 | HCRTR1 (0.49) | HCRTR1HCRTR2MEN1KMT2AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2569310-A1 | MORPHOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | Pfizer Inc (US) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011141848-A1 | MORPHOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER INC. (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20110281854-A1 | MORPHOLINE COMPOUNDS | PFIZER INC | 2011-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281854-A1 | MORPHOLINE COMPOUNDS | REN, MC2R, NR3C2 | HCRTR1 935/4885HCRTR2 621/4885MEN1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.